SenesTech, Inc. is a biotechnology company that has developed a technology for managing animal pest populations, initially rat populations, through fertility control. Its product ContraPest, is in the pest control industry in attacking the reproductive systems of both male and female rats. ContraPest targets the reproductive capabilities of rodents by inducing the gradual loss of eggs in female rodents and disruption of sperm in male rodents, resulting in contraception that can progress to sterility in both females and males. Its pipeline includes feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. Its Feral animal fertility control has its application in the population management segment and targets feral dogs and hogs. Its Non-Surgical Spay and Neutering have its application in companion animal health, and targets companion dogs and cats. The Company`s Boar taint has its application in food production and safety and targets boars.

Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. Gross margin is high, +65.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.12 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Entry Point: Share price is 112.3% higher than minimum and 86.0% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $0.8 mln (20.700% of cap.)